Who are INH preventive therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ethambutol (E), Preventive treatment with Isoniazid, Isoniazid Oral Product, Clofazimine Oral Product, Delamanid + OBR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inh-preventive-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

INH preventive therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

INH preventive therapy (INH preventive therapy) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimycobacterial agent. Area: Infectious Disease.

marketed Antimycobacterial agent InhA (enoyl-ACP reductase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

INH preventive therapy (INH preventive therapy) — Johns Hopkins University. Isoniazid (INH) preventive therapy inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, preventing the development of active tuberculosis in latently infected individuals.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
INH preventive therapy TARGET	INH preventive therapy	Johns Hopkins University	marketed	Antimycobacterial agent	InhA (enoyl-ACP reductase)
Ethambutol (E)	Ethambutol (E)	University College, London	marketed	Antimycobacterial agent	Arabinosyl transferases (EmbA, EmbB, EmbC)
Preventive treatment with Isoniazid	Preventive treatment with Isoniazid	Hospital Universitari de Bellvitge	marketed	Antimycobacterial agent	InhA (enoyl-ACP reductase); KatG (catalase-peroxidase)
Isoniazid Oral Product	Isoniazid Oral Product	Wits Health Consortium (Pty) Ltd	phase 3	Antimycobacterial agent	Enoyl-ACP reductase (InhA), Catalase-peroxidase (KatG)
Clofazimine Oral Product	Clofazimine Oral Product	Wits Health Consortium (Pty) Ltd	phase 3	Antimycobacterial agent	Mycobacterial DNA; reactive oxygen species generation
Delamanid + OBR	Delamanid + OBR	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Nitro-imidazole antimycobacterial agent	Mycolic acid biosynthesis pathway (mycobacterial cell wall)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimycobacterial agent class)

Wits Health Consortium (Pty) Ltd · 2 drugs in this class
Hospital Universitari de Bellvitge · 1 drug in this class
Johns Hopkins University · 1 drug in this class
University College, London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). INH preventive therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/inh-preventive-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing